Vactosertib in Osteosarcoma
Contact
Description
This study involves a taking a study drug called vactosertib by mouth. The overall goal of this study is to find out if vactosertib is a safe and effective treatment for adolescents and adults with recurrent, refractory or progressive Osteosarcoma.
Eligibility and criteria
IRB Number:
22-020384
Eligible age range:
Clinical trial phase:
Phase I
Phase II
Official title:

We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.